Document is current
Any future updates will be listed below
-
Authors
da Cruz, Valeria Lima
Appolinario, Jose Carlos
Sichieri, Rosely
Hay, Phillipa
de Souza Lopes, Claudia
-
Funding
Funding for this research was provided by:
The overall project received financial support from the Investigator Initiated Research Program of Shire (Takeda) Pharmaceuticals. (IIR-REQ-18017330)
- License Information
-
More Information
Article History
Received: 25 November 2024
Accepted: 28 August 2025
First Online: 26 September 2025
Declarations
:
: To carry out the research, approval was obtained from the Ethics Committee of the Federal University of Rio de Janeiro (protocol number CAAE: 03814818.7.0000). The study was conducted by the principles of the Declaration of Helsinki. All participants were informed about the study, and consent was provided written informed consent before enrolling in the study. Also, the chance to withdraw from study at any point was given for the participants.
: Jose C. Appolinario has received research grants, consultancy fees, and advisory board fees from Takeda Pharmaceuticals. He receives/has received royalties/honoraria from Artmed Panamericana Editora. He also received a research grant from the Brazilian National Research Council (CNPq). Phillipa Hay has received sessional fees and lecture fees from the Australian Medical Council, Therapeutic Guidelines publication, and New South Wales Institute of Psychiatry and royalties from Hogrefe and Huber, McGraw Hill Education, and Blackwell Scientific Publications, and she has received research support from CAPES, NHMRC, and ARC. She is Chair of the National Eating Disorders Collaboration in Australia (2019-). She is a consultant for Tryptamine Therapeutics Pharmaceuticals.
